Cleveland Clinic | Strategic Alliance Partners

For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Eric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

December 23, 2020 - Pacritinib, when delivered at a twice-daily dose of 200 mg, was found to demonstrate clinical activity with an acceptable toxicity profile in patients with myelofibrosis and severe thrombocytopenia.

Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Brian T. Hill, MD, PhD, discusses the approval of brexucabtagene autoleucel  in mantle cell lymphoma.

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

During the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Sudipto Mukherjee, MD, PhD, MPH, provides detail as to some of these nuances and the optimal management of patients with CML.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

In our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, reflects on how the approval of CAR T-cell therapy has impacted clinical practice for his patients with MCL, ongoing research with practice-changing implications, and how MCL treatment has evolved during the coronavirus disease 2019 pandemic.

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.